


[illegible]

Entry and consideration of this Amendment is respectfully requested.


Robert J. Seas, Jr.
Registration No. 21,092

3

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

The claims are amended as follows:

- 0988285-11901
3. Method according to claim 1 ~~or claim 2~~, wherein the cells are normal cells.
 4. Method according to claim 1 ~~any of the preceding claims~~, wherein the inhibitor is a selective inhibitor of BCRP.
 5. Method according to claim 1 ~~any of the preceding claims~~, wherein the inhibitor is selected from acridine derivatives, quinoline derivatives, isoquinoline derivatives and combinations thereof.
 6. Method according to claim 1 ~~any of the preceding claims~~, wherein the inhibitor is GF120918, XR 9051 or XR 9576.
 7. Method according to claim 1 ~~any of the preceding claims~~, wherein the bioenhancer is a mycotoxin.
 9. Method according to claim 1 ~~any of the preceding claims~~, wherein the bioenhancer has a higher affinity for BCRP than for P-gp.
 10. Method according to claim 1 ~~any of the preceding claims~~, wherein the bioenhancer has a higher affinity for BCRP than for MRP.
 11. Method according to claim 1 ~~any one of the preceding claims~~, wherein the bioenhancer inhibits binding of ATP to a BCRP mediated and/or related drug transport protein.
 13. Method according to claim 1 ~~any of the preceding claims~~, wherein the pharmaceutically active compound is selected from the group consisting of indolizino-quinoline derivatives, camptothecin derivatives, anthraquinone derivatives and quinazoline derivatives.
 23. Use of a pharmaceutically active compound in combination with a bioenhancer as defined in claim 1 ~~any of the preceding claims~~ as active ingredients in the preparation of a pharmaceutical composition for oral delivery of the pharmaceutically active compound, said

PRELIMINARY AMENDMENT
Attorney Docket No.: Q67353

pharmaceutical composition providing an increased systemic exposure of cells selected from tumor cells and normal cells to said pharmaceutically active compound in comparison to a corresponding pharmaceutical composition in which said bioenhancer is absent.

24. Use of a pharmaceutically active compound in combination with a bioenhancer as defined in claim 1 ~~any of the preceding claims~~ as active ingredients in the preparation of a pharmaceutical composition for oral delivery of the pharmaceutically active compound, said pharmaceutical composition providing an increased reversal of drug resistance in human and animal disorders related to overexpression of BCRP.
27. Use of a compound selected according to claim 26 as bioenhancer in a pharmaceutical composition ~~according to claim 22~~.